Added to YB: 2024-05-17
Pitch date: 2024-05-15
INBX [bullish]
Inhibrx, Inc.
-0.79%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates.
Market Cap
$1.8B
Pitch Price
$30.87
Price Target
38.00 (+24%)
Dividend
N/A
EV/EBITDA
-7.10
P/E
-6.27
EV/Sales
979.16
Sector
Biotechnology
Category
special_situation
Inhibrx Inc: Cash Buyout + SpinCo (Inhibrx Biosciences) and CVR
INBX: Sanofi acquiring INBX-101 AAT deficiency treatment for $30/sh cash + 92% of remaining pipeline (oncology assets INBRX-106/109) via SpinCo. CVR pays $5/sh on FDA approval by 6/30/27, valued at $2.05 NPV. SpinCo worth $5.85-$7.95/0.25 sh, seeded w/ $200M cash for ~1yr runway. $38/sh value vs $34.20 trading price.
Read full article (5 min)